One means of achieving this by localising the antibody in the tumor, such as exemplified by GEN1046, an antibody targeting 4-1BB and PD-L1, wherein the MTD was not reached at a dose >10 mg/kg and the safety profile was manageable.(87). This evidence concerns the gene CD274 and neoplasm.